• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Rallybio Unveils Q3 2025 Financials & Business Updates

    BUSINESSWIRE

    Rallybio Starts Dosing in RLYB116 Phase 1 PK/PD Study

    BUSINESSWIRE

    Rallybio Downsizes by 40% After Dropping Lead Asset

    BIOSPACE

    Rallybio Reports Q4 and Full Year 2024 Results, Business Updates

    BUSINESSWIRE

    Rallybio to Present at the TD Cowen Annual Health Care Conference

    BUSINESSWIRE

    Rallybio Announces Initiation of Dosing in RLYB212 Ph 2 Trial

    BUSINESSWIRE

    Rallybio Shares RLYB212, RLYB332 Data At ASH Meeting

    BUSINESSWIRE

    Rallybio to Initiate RLYB116 Clinical PK/PD Study in 2025

    BUSINESSWIRE

    Rallybio`s Publication on RLYB212 Dosing Regimen in Pregnant Women

    BUSINESSWIRE

    Rallybio to Present at 2024 Evercore ISI HealthCONx Conference

    BUSINESSWIRE

    Rallybio to Provide Update on RLYB116 Subcutaneous C5 Inhibitor

    BUSINESSWIRE

    Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

    BUSINESSWIRE

    Rallybio Reports Q3 2024 Financial Results & Business Updates

    BUSINESSWIRE

    Rallybio Approves Phase 2 Trial of RLYB212 for Pregnant Women

    BUSINESSWIRE

    Rallybio To Present FNAIT Risk Analysis At ASHG 2024 Meeting

    BUSINESSWIRE

    Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

    BUSINESSWIRE

    Rallybio Reports Q2 2024 Results And Business Updates

    BUSINESSWIRE

    Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116

    BUSINESSWIRE

    Rallybio Announces Multiple Dose Data from the Completed Phase 1 of RLYB212

    BUSINESSWIRE

    Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116

    BUSINESSWIRE

    Rallybio Announces Acceptance of Abstract for RLYB116 at ICW

    BUSINESSWIRE

    Rallybio Announces Clinical Proof-of-Concept Results for RLYB211

    BUSINESSWIRE

    Rallybio Announces Acceptance of Abstract for RLYB212 at ISTH

    BUSINESSWIRE

    Rallybio Announces Proof-of-Concept Achieved for RLYB212

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.